Latest stories on LEGN
Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results
GlobeNewswire50 · neutralearnings
Legend Biotech: Carvykti Makes Billions, But The Profits Are Elusive
Seeking Alpha63 · neutralearnings
Legend Biotech Wins FDA IND Clearance for First Dual-Target In Vivo CAR-T LB2501
TipRanks74 · bullishproduct/pr
Legend Biotech announces FDA clearance of LB2501 IND application
The Fly64 · neutralproduct/pr
Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy
GlobeNewswire74 · bullishproduct/pr
H.C. Wainwright reiterates Legend Biotech stock rating on strong Carvykti sales
Investing.com Analyst Ratings63 · neutralanalyst
Legend Biotech Posts Preliminary $710 Million Quarterly Sales for CARVYKTI®
TipRanks64 · neutralearnings
Legend Biotech price target lowered to $68 from $74 at Barclays
The Fly34 · bearishanalyst
Legend Biotech price target lowered to $33 from $35 at JPMorgan
The Fly34 · bearishanalyst
Legend Biotech price target lowered to $56 from $58 at RBC Capital
The Fly34 · bearishanalyst
Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
Business Insider56 · neutralproduct/pr
Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
GlobeNewswire63 · neutralproduct/pr
H.C. Wainwright reiterates Legend Biotech stock rating on durability data
Investing.com Analyst Ratings56 · neutralanalyst
Legend Biotech announces five-year follow-up data from Cartitude-2 Cohort A
The Fly63 · neutralproduct/pr
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
Business Insider73 · bullishproduct/pr
10 mid-cap U.S. healthcare stocks with the weakest momentum grades
Seeking Alpha32 · bearishgeneral
LEGN’s New CEO From Novartis Paves Way For Buyout Speculation
Stocktwits News58 · neutralgeneral
Legend Biotech appoints Ingrid Zhang as CEO
Seeking Alpha50 · neutralgeneral
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
GlobeNewswire56 · neutralgeneral
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
Business Insider56 · neutralgeneral
LEGN.CN Trading Strategies for Legion Metals Corp Stock
Barchart50 · neutralgeneral
Legend Biotech price target lowered to $74 from $78 at Barclays
The Fly42 · neutralanalyst